ArticleMikrochimica acta2026
Portable single-step ethanolamine-functionalized boron-doped diamond immunosensor for dual detection of CEA and CYFRA 21-1.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A single-step ethanolamine-functionalized boron-doped diamond (BDD) immunosensor for the dual detection of carcinoembryonic antigen (CEA) and cytokeratin fragment 21-1 (CYFRA 21-1). Unlike conventional multi-step carbodiimide-based coupling strategies, the ethanolamine (ETA) modification provides a simplified amine-terminated surface for efficient antibody immobilization. Comprehensive characterization confirmed successful layer-by-layer assembly: scanning electron microscopy (SEM) revealed surface morphological evolution, while X-ray photoelectron spectroscopy (XPS), Contact angle measurements and attenuated total reflectance Fourier-transform infrared spectroscopy (ATR-FTIR) verified amine group integration and biomarker attachment. The platform showed concentration-dependent current responses across the range of 0.001-400 ng/mL and achieved statistically calculated limits of detection of 0.085 pg/mL for CEA and 0.043 pg/mL for CYFRA 21-1. The sensor exhibited good selectivity, reproducibility, stability, and reliable performance in spiked human serum samples with minimal matrix interference. In addition, an Arduino-based portable readout closely matched bench-top measurements, supporting the potential of the platform for point-of-care lung cancer screening.
Indexed as
Identifiers
42789118What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.